



PRESS RELEASE

Zutphen, the Netherlands, 18 December 2014

EGM appoints EY as external auditor

Esperite N.V. (Euronext: ESP, 'Esperite', or 'the Group'), the European leader in stem cells cryopreservation, now entering the fields of predictive medicine and translational regenerative medicine R&D, announces that all resolutions of today's extra-ordinary general meeting of shareholders ("EGM") were passed and that EY Accountants LLP was appointed as external auditor for a term of 1-year.

Enquiries: Cryo-Save Group
Frédéric Amar, Chief Executive Officer

+ 31 (0) 575 548 998

About Esperite (www.esperite.com)

Esperite, the leading international company in regenerative and predictive medicine. Its family stem cell bank, CryoSave, stores almost 275,000 samples from umbilical cord blood and cord tissue. There are already many diseases treatable by the use of stem cells, and the number of treatments will only increase. Esperite has cryopreserved samples from over 70 countries on six continents, with ultra-modern processing and storage facilities in Belgium, Switzerland, Germany, Dubai, South Africa and Portugal.